SNDL Valuation
Is VY4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of VY4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VY4 (€1.9) is trading above our estimate of fair value (€0.4)
Significantly Below Fair Value: VY4 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VY4?
Key metric: As VY4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is VY4's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | CA$911.22m |
| Market Cap | CA$734.99m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | -11.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VY4's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.2x | ||
PSG PharmaSGP Holding | 2.6x | 7.7% | €287.8m |
93M1 MPH Health Care | 0.9x | -60.2% | €105.3m |
DMP Dermapharm Holding | 1.7x | 4.1% | €2.0b |
2FJ0 Pierrel | 3.4x | n/a | €92.8m |
VY4 SNDL | 0.8x | 7.2% | €525.7m |
Price-To-Sales vs Peers: VY4 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2.2x).
Price to Sales Ratio vs Industry
How does VY4's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: VY4 is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is VY4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 1.6x |
Price-To-Sales vs Fair Ratio: VY4 is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.90 | €3.25 +71.0% | 14.5% | €3.72 | €2.78 | n/a | 2 |
| Nov ’25 | €1.92 | €3.32 +72.7% | 9.3% | €3.63 | €3.01 | n/a | 2 |
| Oct ’25 | €1.83 | €3.32 +81.1% | 9.3% | €3.63 | €3.01 | n/a | 2 |
| Sep ’25 | €1.76 | €3.31 +88.3% | 10.3% | €3.65 | €2.97 | n/a | 2 |
| Aug ’25 | €2.11 | €3.33 +57.6% | 10.9% | €3.69 | €2.96 | n/a | 2 |
| Jul ’25 | €1.74 | €3.37 +93.1% | 10.7% | €3.73 | €3.01 | n/a | 2 |
| Jun ’25 | €2.04 | €3.37 +64.8% | 10.4% | €3.72 | €3.01 | n/a | 2 |
| May ’25 | €2.32 | €3.34 +44.2% | 10.6% | €3.70 | €2.99 | n/a | 2 |
| Apr ’25 | €1.91 | €3.34 +75.0% | 10.6% | €3.70 | €2.99 | n/a | 2 |
| Mar ’25 | €1.23 | €3.38 +175.7% | 9.7% | €3.70 | €3.05 | n/a | 2 |
| Feb ’25 | €1.25 | €3.38 +171.0% | 9.7% | €3.70 | €3.05 | n/a | 2 |
| Jan ’25 | €1.51 | €3.38 +123.4% | 9.7% | €3.70 | €3.05 | n/a | 2 |
| Dec ’24 | €1.33 | €3.34 +151.0% | 10.2% | €3.69 | €3.00 | n/a | 2 |
| Jun ’24 | €1.30 | €3.01 +132.0% | 0.6% | €3.02 | €2.99 | €2.04 | 2 |
| May ’24 | €1.31 | €2.97 +126.2% | 0.02% | €2.97 | €2.96 | €2.32 | 2 |
| Apr ’24 | €1.46 | €3.20 +118.9% | 11.0% | €3.69 | €2.74 | €1.91 | 4 |
| Mar ’24 | n/a | €3.20 0% | 11.0% | €3.69 | €2.74 | €1.23 | 4 |
| Feb ’24 | n/a | €3.20 0% | 11.0% | €3.69 | €2.74 | €1.25 | 4 |
| Jan ’24 | n/a | €3.22 0% | 10.9% | €3.71 | €2.76 | €1.51 | 4 |
| Dec ’23 | n/a | €3.31 0% | 11.3% | €3.84 | €2.86 | €1.33 | 4 |
| Nov ’23 | n/a | €3.48 0% | 14.4% | €4.11 | €2.89 | €1.36 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R74.3b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R9.00
7D
0.6%
1Y
5.3%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.45
7D
1.1%
1Y
2.9%